← Back to headlines
Ultragenyx Receives FDA IND Clearance for UX016 in GNE Myopathy Treatment
Ultragenyx has announced that its investigational new drug (IND) application for UX016, intended for the treatment of GNE myopathy, has received clearance from the FDA.
30 Mar, 14:38 — 30 Mar, 14:38
Sources
Showing 1 of 1 sources
Related Stories
Magnitude 4 Quakes Strike Romania and New Zealand
9h ago
Indonesian Authorities Maintain Alert as Mount Anak Krakatau Continues Erupting
1d ago
Severe Algae Bloom Threatens Israel’s Desalination Infrastructure and Water Supply
1d ago
Ig Nobel Prizes Awarded at First Ceremony Held Outside the United States
2d ago